Results · Apr-Jun 2026
Astec Lifesciences Q1 FY27 results
Sales fell 8% to ₹83.6 crore from ₹91.1 crore in Apr-Jun 2025.
Operating profit was −₹0.67 crore, an operating margin of −0.8% (up 11.3 points from a year ago).
The net loss narrowed to ₹18.7 crore from ₹33 crore.
Against Jan-Mar 2026: sales −47%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 83.6 | 91.1 | −8% |
| Operating profit (EBITDA) | -0.7 | -11.0 | n/m |
| Operating margin | −0.8% | −12.1% | +11.3 pts |
| Net profit | -18.7 | -33.0 | loss narrows |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.